No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.
References
[1]
Garbe, C.; Eigentler, T.K.; Keilholz, U.; Hauschild, A.; Kirkwood, J.M. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 2011, 16, 5–24.
[2]
Katz, K.A.; Jonasch, E.; Hodi, F.S.; Soiffer, R.; Kwitkiwski, K.; Sober, A.J.; Haluska, F.G. Melanoma of unknown primary: Experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005, 15, 77–82, doi:10.1097/00008390-200502000-00013.
[3]
Jacobs, J.J.; Sparendam, D.; den Otter, W. Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol. Immunother. 2005, 54, 647–654, doi:10.1007/s00262-004-0627-4.
[4]
Weide, B.; Derhovanessian, E.; Pflugfelder, A.; Eigentler, T.K.; Radny, P.; Zelba, H.; Pf？hler, C.; Pawelec, G.; Garbe, C. High response rate after intratumoral treatment with interleukin-2: Results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010, 116, 4139–4146, doi:10.1002/cncr.25156.
[5]
Babilas, P.; Shafirstein, G.; Baumler, W.; Baier, J.; Landthaler, M.; Szeimies, R.M.; Abels, C. Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: In vivo results and mathematical modelling are in agreement. J. Invest. Dermatol. 2005, 125, 343–352.
[6]
Van der Zee, J. Heating the patient: A promising approach? Ann. Oncol. 2002, 13, 1173–1184, doi:10.1093/annonc/mdf280.
